Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
302 DKK | +1.00% | -10.65% | +141.60% |
Apr. 17 | Gubra Unveils UCN2 as Novel Anti-Obesity Drug Candidate for Healthy Weight Loss | CI |
Mar. 29 | Certain Shares of Gubra A/S are subject to a Lock-Up Agreement Ending on 29-MAR-2024. | CI |
Sales 2022 | 199M 29.05M | Sales 2023 | 205M 29.87M | Capitalization | 2.04B 297M |
---|---|---|---|---|---|
Net income 2022 | 4M 583K | Net income 2023 | -44M -6.41M | EV / Sales 2022 * | - |
Net cash position 2022 | 2.52M 367K | Net cash position 2023 | 386M 56.23M | EV / Sales 2023 | 8.05 x |
P/E ratio 2022 * |
-
| P/E ratio 2023 |
-42.6
x | Employees | 220 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 30.58% |
1 day | +1.00% | ||
1 week | -10.65% | ||
Current month | -0.66% | ||
1 month | +4.14% | ||
3 months | +94.84% | ||
6 months | +159.23% | ||
Current year | +141.60% |
Managers | Title | Age | Since |
---|---|---|---|
Niels Vrang
FOU | Founder | 56 | 07-12-31 |
Henrik Blou
CEO | Chief Executive Officer | 45 | 16-05-31 |
Kristian Borbos
DFI | Director of Finance/CFO | 46 | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 58 | 21-12-31 | |
Director/Board Member | 48 | 21-12-31 | |
Jacob Jelsing
FOU | Founder | 50 | 07-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 302 | +1.00% | 19,888 |
24-05-16 | 299 | +0.67% | 19,005 |
24-05-15 | 297 | +0.68% | 27,524 |
24-05-14 | 295 | -3.28% | 53,712 |
Delayed Quote Nasdaq Copenhagen, May 17, 2024 at 10:59 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+141.60% | 717M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- GUBRA Stock